Docetaxel Patent Expiration
Docetaxel is used for the treatment of hormone-refractory metastatic prostate cancer, non-small cell lung cancer, and operable node-positive breast cancer. It was first introduced by Sanofi Aventis Us Llc
Docetaxel Patents
Given below is the list of patents protecting Docetaxel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Beizray | US11419842 | Neutral pH compositions of Docetaxel and human serum albumin | May 16, 2036 | Zhuhai |
| Beizray | US12090134 | Neutral pH compositions of docetaxel and human serum albumin | May 16, 2036 | Zhuhai |
| Beizray | US12090135 | Neutral pH compositions of docetaxel and human serum albumin | May 16, 2036 | Zhuhai |
| Docivyx | US10398785 | Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use | Mar 14, 2036 | Avyxa Holdings |
| Docetaxel | US8940786 | Non-aqueous taxane nanodispersion formulations and methods of using the same | Sep 30, 2033 | Shilpa |
| Docetaxel | US9308195 | Non-aqueous taxane formulations and methods of using the same | Sep 30, 2033 | Shilpa |
| Docetaxel | US9763880 | Non-aqueous taxane formulations and methods of using the same | Sep 30, 2033 | Shilpa |
| Docetaxel | US10842770 | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | Aug 07, 2031 | Shilpa |
| Taxotere |
US5438072 (Pediatric) | Taxoid-based compositions |
May 22, 2014
(Expired) | Sanofi Aventis Us |
| Taxotere | US5438072 | Taxoid-based compositions |
Nov 22, 2013
(Expired) | Sanofi Aventis Us |
| Taxotere |
US5698582 (Pediatric) | Compositions containing taxane derivatives |
Jan 03, 2013
(Expired) | Sanofi Aventis Us |
| Taxotere |
US5714512 (Pediatric) | Compositions containing taxane derivatives |
Jan 03, 2013
(Expired) | Sanofi Aventis Us |
| Taxotere |
US5750561 (Pediatric) | Compositions containing taxane derivatives |
Jan 03, 2013
(Expired) | Sanofi Aventis Us |
| Taxotere | US5698582 | Compositions containing taxane derivatives |
Jul 03, 2012
(Expired) | Sanofi Aventis Us |
| Taxotere | US5714512 | Compositions containing taxane derivatives |
Jul 03, 2012
(Expired) | Sanofi Aventis Us |
| Taxotere | US5750561 | Compositions containing taxane derivatives |
Jul 03, 2012
(Expired) | Sanofi Aventis Us |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Docetaxel's patents.
Latest Legal Activities on Docetaxel's Patents
Given below is the list recent legal activities going on the following patents of Docetaxel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 May, 2024 | US10842770 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2023 | US9308195 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jul, 2022 | US8940786 |
| Post Issue Communication - Certificate of Correction | 18 May, 2021 | US10842770 |
| Email Notification Critical
| 13 May, 2021 | US10842770 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 12 May, 2021 | US10842770 |
| Mail-Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 12 May, 2021 | US10842770 |
| Record a Petition Decision of Granted for Patent Term Adjustment after Issue | 11 May, 2021 | US10842770 |
| Pet Dec Routed to Certificate of Corrections Branch | 11 May, 2021 | US10842770 |
| Adjustment of PTA Calculation by PTO | 11 May, 2021 | US10842770 |
Docetaxel's Family Patents
